Infinity Pharmaceuticals
Randall Kester has extensive experience in supervisory roles, currently serving as Superintendent at Infinity Pharmaceuticals since April 2013. Prior to this position, Randall Kester held a Superintendent role at CMF Ltd for a brief period in 2014. The focus of Randall Kester's professional responsibilities has been on timely project execution and financial profitability. Randall Kester is an alumnus of Hunter Huss High School.
This person is not in any offices
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.